Business Context and Reporting Period
This Form 8-K was filed by TRxADE HEALTH, Inc. (noting a discrepancy with the request metadata which listed "Scienture Holdings, Inc.") on October 4, 2023. The company is a Delaware corporation headquartered in Lutz, Florida, with common stock trading on The Nasdaq Stock Market under the symbol MEDS. The filing reports a private placement transaction and the designation of a new class of preferred stock.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than standard operating financial results. Key metrics from the transaction include:
- Gross Proceeds: $290,000.
- Securities Issued:
- 290 shares of Series C Convertible Preferred Stock (Stated Value: $1,000 per share).
- Warrant to purchase up to 41,193 shares of Common Stock (Exercise Price: $7.20 per share).
- 40,000 shares of Common Stock (Commitment Shares).
- Investor: Hudson Global Ventures, LLC.
- Liquidity: The filing explicitly states there is no established trading market for the Series C Preferred Stock, and liquidity is expected to be limited.
The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Terms
The primary material change is the issuance of the Series C Preferred Stock with aggressive investor protections and conversion mechanics:
- Conversion Price: Set at the lower of 85% of the average of the two lowest VWAPs in the 10 days prior to conversion or the 5 days prior to closing. In the event of a "Triggering Event," the price drops to the lowest of $5.00, the then-applicable price, or 25% of the lowest traded price in the preceding 15 days.
- Redemption Rights: The company may redeem shares at a premium (1.15x to 1.25x stated value) within 180 days. Holders have a right to force redemption at 135% of the stated value plus accrued dividends and fees upon a Triggering Event.
- Dividends: No cash dividends are paid unless paid on Common Stock. However, upon a Triggering Event, the dividend rate increases to 18% per annum.
- Most Favored Nation: Holders can exchange their preferred stock for securities issued in subsequent financings on a $1.00 for $1.00 basis.
Guidance, Risks, and Contingencies
The filing outlines significant risks and covenants associated with the new securities:
- Negative Covenants: Until the Series C Preferred Stock is no longer outstanding, the company is restricted from repurchasing common stock or junior securities, and cannot enter into affiliate transactions without specific board approval.
- Registration Rights: The company must file a registration statement for the underlying common stock within 15 days of issuance.
- Beneficial Ownership Limitation: Conversion is capped to prevent any holder from beneficially owning more than 4.99% of the outstanding common stock.
- Triggering Event Risk: The definition of a "Triggering Event" is not detailed in the summary text but triggers severe financial penalties (135% redemption price) and increased dividend rates (18%).
Investor Verification Checklist
- Verify the exact definition of a "Triggering Event" in the attached Certificate of Designation (Exhibit 3.1) to understand the conditions for forced redemption.
- Confirm the current cash position of TRxADE HEALTH, Inc. to assess the ability to meet potential redemption obligations (up to 135% of stated value plus fees).
- Review the company's recent stock price history to calculate the potential dilution impact of the 85% discount conversion price and the warrant exercise price of $7.20.
- Check for any subsequent filings regarding the registration statement required within 15 days of the October 4 issuance.